AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23547078 — intervention group
Group type: COMPARATOR
Intervention: Observation (NM)
Number of subjects: 280
Study 23547078 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab purging (P+)
Number of subjects: 280
Study 23547078 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (M+)
Number of subjects: 280
Study 20952020 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 100
Study 20952020 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 100
Study 18171718 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based occupational therapy (10 sessions over five weeks)
Number of subjects: 135
Study 18171718 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based occupational therapy
Number of subjects: 135
Study 18171718 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 135
Study 17148797 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia followed by postoperative intravenous patient‐controlled analgesia with morphine
Number of subjects: 60
Study 17148797 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal‐epidural anaesthesia followed by postoperative epidural infusion of bupivacaine 0.1% with fentanyl 2 microg/mL
Number of subjects: 60
Study 15272949 — intervention group
Group type: EXPERIMENTAL
Intervention: High power group with illegitimate power hierarchy
Number of subjects: 230
Study 15272949 — intervention group
Group type: EXPERIMENTAL
Intervention: Low power group with illegitimate power hierarchy
Number of subjects: 230
Study 15272949 — intervention group
Group type: COMPARATOR
Intervention: High power group with legitimate power hierarchy
Number of subjects: 230
Study 15272949 — intervention group
Group type: COMPARATOR
Intervention: Low power group with legitimate power hierarchy
Number of subjects: 230
Study 15272949 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups within an unfair power hierarchy
Number of subjects: 230
Study 15272949 — intervention group
Group type: COMPARATOR
Intervention: Groups with legitimately high or low power
Number of subjects: 230
Study 10743873 — intervention group
Group type: EXPERIMENTAL
Intervention: High anger feedback
Number of subjects: 0
Study 10743873 — intervention group
Group type: EXPERIMENTAL
Intervention: Dishonesty feedback
Number of subjects: 0
Study 10743873 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger induction (insulted participants)
Number of subjects: 0
Study 10743873 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbalizing emotions about being insulted
Number of subjects: 0
Study 8785144 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 200 mg i.v.
Number of subjects: 51
Study 8785144 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg i.v.
Number of subjects: 51
Study 8785144 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 51
Study 1488688 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (4 tablets, 1000 mg) plus tetracycline (250 mg qid for 7 days)
Number of subjects: 51
Study 1488688 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP (4 tablets, one tablet contains 250 mg mefloquine, 500 mg sulfadoxine and 25 mg pyrimethamine) plus tetracycline (250 mg qid for 7 days)
Number of subjects: 51
Study 3698068 — intervention group
Group type: EXPERIMENTAL
Intervention: 750-ml spacer
Number of subjects: 40
Study 3698068 — intervention group
Group type: COMPARATOR
Intervention: ordinary MDI
Number of subjects: 40
Study 31663986 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week resistance band exercise training (EX, n=10)
Number of subjects: 20
Study 31663986 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON, n=10)
Number of subjects: 20
Study 29767326 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence-supported extended pelvic lymph node dissection (ICG-ePLND)
Number of subjects: 120
Study 29767326 — intervention group
Group type: COMPARATOR
Intervention: Regular extended pelvic lymph node dissection (ePLND)
Number of subjects: 120
Study 29767326 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-ePLND
Number of subjects: 120
Study 29767326 — intervention group
Group type: COMPARATOR
Intervention: Regular ePLND
Number of subjects: 120
Study 29767326 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 27586072 — intervention group
Group type: EXPERIMENTAL
Intervention: STP-PreK Enhanced
Number of subjects: 45
Study 27586072 — intervention group
Group type: EXPERIMENTAL
Intervention: STP-PreK
Number of subjects: 45
Study 27586072 — intervention group
Group type: EXPERIMENTAL
Intervention: SRPP
Number of subjects: 45
Study 27586072 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard behavioral modification system and academic curriculum)
Number of subjects: 45
Study 23932140 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized heparin sulfate 10,000 IU
Number of subjects: 29
Study 23932140 — intervention group
Group type: COMPARATOR
Intervention: Nebulized heparin sulfate 5,000 IU
Number of subjects: 29
Study 23932140 — intervention group
Group type: COMPARATOR
Intervention: Control (N-acetylcysteine)
Number of subjects: 29
Study 22452973 — intervention group
Group type: COMPARATOR
Intervention: Arm endurance training
Number of subjects: 52
Study 22452973 — intervention group
Group type: COMPARATOR
Intervention: Combined arm endurance and strength training
Number of subjects: 52
Study 22452973 — intervention group
Group type: COMPARATOR
Intervention: Arm strength training
Number of subjects: 52
Study 22452973 — intervention group
Group type: EXPERIMENTAL
Intervention: No arm training (control group)
Number of subjects: 52
Study 20139111 — intervention group
Group type: EXPERIMENTAL
Intervention: naïve simulator
Number of subjects: 82
Study 20139111 — intervention group
Group type: EXPERIMENTAL
Intervention: coached simulator
Number of subjects: 82
Study 20139111 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 82
Study 20139111 — intervention group
Group type: EXPERIMENTAL
Intervention: average to peak force ratio
Number of subjects: 82
Study 20139111 — intervention group
Group type: EXPERIMENTAL
Intervention: Word Memory Test (WMT)
Number of subjects: 82
Study 18332450 — intervention group
Group type: EXPERIMENTAL
Intervention: IV iron sucrose (200 mg iron) once per week for 4 weeks then once every other week for a further 4 weeks
Number of subjects: 46
Study 18332450 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous succinate, 200 mg three times per day for 8 weeks
Number of subjects: 46
Study 18332450 — intervention group
Group type: EXPERIMENTAL
Intervention: IV iron sucrose
Number of subjects: 46
Study 15757578 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbalizing groups
Number of subjects: 48
Study 15757578 — intervention group
Group type: COMPARATOR
Intervention: Nonverbalizing groups
Number of subjects: 48
Study 15757578 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups with 1-2 player replacements
Number of subjects: 48
Study 15757578 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups with 3 player replacements
Number of subjects: 48
Study 12602671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pari Inhalierboy (2 mg budesonide)
Number of subjects: 12
Study 12602671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pari LC Jet Plus (2 mg budesonide)
Number of subjects: 12
Study 12602671 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxin MA-2 (2 mg budesonide)
Number of subjects: 12
Study 12602671 — intervention group
Group type: COMPARATOR
Intervention: 4 mg budesonide orally
Number of subjects: 12
Study 12602671 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg budesonide intravenously
Number of subjects: 12
Study 10584978 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid 500 mg/day for 28 days (group B)
Number of subjects: 30
Study 10584978 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid 500 mg/day for 14 days (group A)
Number of subjects: 30
Study 10584978 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 30
Study 8947990 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumatrak method for INR determination
Number of subjects: 32
Study 8947990 — intervention group
Group type: COMPARATOR
Intervention: Conventional laboratory method for INR determination
Number of subjects: 32
Study 8947990 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention in managing warfarin therapy
Number of subjects: 32
Study 1835223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous teicoplanin
Number of subjects: 75
Study 1835223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular teicoplanin
Number of subjects: 75
Study 7195047 — intervention group
Group type: EXPERIMENTAL
Intervention: First breast
Number of subjects: 24
Study 7195047 — intervention group
Group type: COMPARATOR
Intervention: Second breast
Number of subjects: 24
Study 7195047 — intervention group
Group type: COMPARATOR
Intervention: Second breast (while feeding from the first)
Number of subjects: 24
Study 30844804 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 50
Study 30844804 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (SED)
Number of subjects: 50
Study 28977574 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hours/night time-in-bed (short sleep)
Number of subjects: 30
Study 28977574 — intervention group
Group type: COMPARATOR
Intervention: 9 hours/night time-in-bed (long sleep)
Number of subjects: 30
Study 25733629 — intervention group
Group type: EXPERIMENTAL
Intervention: CFR intervention (optimized complementary feeding recommendations)
Number of subjects: 240
Study 25733629 — intervention group
Group type: EXPERIMENTAL
Intervention: CFR group
Number of subjects: 240
Study 24732048 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunity to take part in the trial (opt-in)
Number of subjects: 124
Study 24732048 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunity to be removed from the trial (opt-out)
Number of subjects: 124
Study 24732048 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice to have standard treatment or take part in the trial (choice)
Number of subjects: 124
Study 24732048 — intervention group
Group type: EXPERIMENTAL
Intervention: Full information in patient decision aid format
Number of subjects: 124
Study 22168274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine alone
Number of subjects: 777
Study 22168274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine with cyclophosphamide (FC)
Number of subjects: 777
Study 22168274 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 777
Study 22168274 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained remissions
Number of subjects: 777
Study 22168274 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease progression
Number of subjects: 777
Study 19719498 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial appendage (RAA) stimulation
Number of subjects: 25
Study 19719498 — intervention group
Group type: COMPARATOR
Intervention: Bachmann's Bundle (BB) stimulation
Number of subjects: 25
Study 17889679 — intervention group
Group type: EXPERIMENTAL
Intervention: One-visit treatment
Number of subjects: 101
Study 17889679 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-visit treatment
Number of subjects: 101
Study 17889679 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative microbiologic sample
Number of subjects: 101
Study 17889679 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive microbiologic sample
Number of subjects: 101
Study 17889679 — intervention group
Group type: COMPARATOR
Intervention: Comparison between one-visit and two-visit treatments
Number of subjects: 101
Study 15209452 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation, exercise, and physician consultation
Number of subjects: 204
Study 15209452 — intervention group
Group type: COMPARATOR
Intervention: Consultation alone
Number of subjects: 204
Study 12218286 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol ointment (2%) once daily for 30 min + vehicle of calcipotriol (50 microg/g) twice daily
Number of subjects: 46
Study 12218286 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol ointment (2%) once daily for 30 min + calcipotriol (50 microg/g) twice daily
Number of subjects: 46
Study 10972606 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-ketamine
Number of subjects: 78
Study 10972606 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-enflurane (controls)
Number of subjects: 78
Study 8641492 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily hMG beginning on cycle day 3 (Group A)
Number of subjects: 0
Study 8641492 — intervention group
Group type: COMPARATOR
Intervention: Combination of CC days 3 through 7 followed by hMG from day 7 onward (Group B)
Number of subjects: 0
Study 1295525 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexamethasone 0.1% (Maxidex)
Number of subjects: 184
Study 1295525 — intervention group
Group type: COMPARATOR
Intervention: Topical fluorometholone 0.1% (FML Liquifilm)
Number of subjects: 184
Study 1295525 — intervention group
Group type: COMPARATOR
Intervention: Topical naphazoline hydrochloride 0.1% (Albalon)
Number of subjects: 184
Study 1295525 — intervention group
Group type: COMPARATOR
Intervention: Combined treatments (FML and Albalon)
Number of subjects: 184
Study 6470194 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine tablets
Number of subjects: 0
Study 6470194 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine suspension
Number of subjects: 0
Study 6470194 — intervention group
Group type: COMPARATOR
Intervention: Thioridazine tablets and suspension (comparison)
Number of subjects: 0
Study 31210092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive residential rehabilitation
Number of subjects: 256
Study 31210092 — intervention group
Group type: COMPARATOR
Intervention: Residential supported living
Number of subjects: 256
Study 29381827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and hygiene education intervention
Number of subjects: 399
Study 29381827 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 399
Study 26845375 — intervention group
Group type: EXPERIMENTAL
Intervention: High-reinforcement (HR) condition
Number of subjects: 403
Study 26845375 — intervention group
Group type: COMPARATOR
Intervention: Low-reinforcement (LR) condition
Number of subjects: 403
Study 26845375 — intervention group
Group type: EXPERIMENTAL
Intervention: Program completers
Number of subjects: 403
Study 26845375 — intervention group
Group type: COMPARATOR
Intervention: Non-completers
Number of subjects: 403
Study 24885032 — intervention group
Group type: EXPERIMENTAL
Intervention: Home jejunostomy feeding for six weeks after discharge
Number of subjects: 60
Study 24885032 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control)
Number of subjects: 60
Study 22525206 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg once per day)
Number of subjects: 360
Study 22525206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 20581787 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg/day for 8 weeks
Number of subjects: 20
Study 20581787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18346881 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (100 mg/day)
Number of subjects: 49
Study 16249219 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab plus stenting
Number of subjects: 300
Study 16249219 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus stenting
Number of subjects: 300
Study 14530158 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered fractionation schemes based on different radiobiological mechanisms; specific dosage and duration not available.
Number of subjects: 0
Study 14530158 — intervention group
Group type: COMPARATOR
Intervention: Retrospective clinical data analysis; specific intervention details not available.
Number of subjects: 0
Study 10487657 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (transdermal 17beta‐estradiol, 50 microg/day; plus oral norethisterone acetate, 1 mg/day)
Number of subjects: 100
Study 10487657 — intervention group
Group type: EXPERIMENTAL
Intervention: MFP (oral monofluorophosphate, 20 mg/day)
Number of subjects: 100
Study 10487657 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT+MFP
Number of subjects: 100
Study 10487657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8765440 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day continuous etoposide infusion at doses from 30 to 75 mg/m2 per day (schedule A)
Number of subjects: 54
Study 8765440 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-day continuous etoposide infusion at doses from 18 to 40 mg/m2 per day (schedule B)
Number of subjects: 54
Study 1837047 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 300
Study 1837047 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 300
Study 1837047 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued treatment by the general practitioner
Number of subjects: 300
Study 1837047 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 300
Study 30959516 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes (PROs) included in trials
Number of subjects: 49568
Study 30959516 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials publishing PRO results
Number of subjects: 49568
Study 30959516 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting standards for PRO findings
Number of subjects: 49568
Study 30959516 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with inadequate PRO protocol content
Number of subjects: 49568
Study 30959516 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with delayed PRO publication
Number of subjects: 49568
Study 30959516 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with very delayed PRO publication
Number of subjects: 49568
Study 29429636 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg/day
Number of subjects: 7141
Study 29429636 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg/day
Number of subjects: 7141
Study 29429636 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (overall)
Number of subjects: 7141
Study 29429636 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (new users)
Number of subjects: 7141
Study 29429636 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (current users)
Number of subjects: 7141
Study 29429636 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (low-risk patients, CHADS2 0-1)
Number of subjects: 7141
Study 27129580 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical hypnosis
Number of subjects: 66
Study 27129580 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 66
Study 24786582 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology intervention
Number of subjects: 39
Study 24786582 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 39
Study 22336235 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome (135 mg/m²)
Number of subjects: 69
Study 22336235 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel liposome plus oxaliplatin (135 mg/m² + 125 mg/m²)
Number of subjects: 69
Study 21030905 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with reduced calcineurin inhibitor exposure
Number of subjects: 245
Study 21030905 — intervention group
Group type: COMPARATOR
Intervention: Control (CNI-based immunosuppression)
Number of subjects: 245
Study 21030905 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 245
Study 21030905 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 245
Study 17823041 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient oral hydration and N‐acetylcysteine
Number of subjects: 78
Study 17823041 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient hydration plus N‐acetylcysteine
Number of subjects: 78
Study 17823041 — intervention group
Group type: COMPARATOR
Intervention: Inpatient intravenous hydration alone (standard therapy)
Number of subjects: 78
Study 15950436 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 195
Study 15950436 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 195
Study 11809337 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg progesterone/g cream
Number of subjects: 24
Study 11809337 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg progesterone/g cream
Number of subjects: 24
Study 11809337 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 24
Study 10416252 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium fluorescein solution applied with Pulmicort Topinasal (budesonide) metered pump bottles
Number of subjects: 18
Study 10416252 — intervention group
Group type: EXPERIMENTAL
Intervention: Application during the decongested phase of the nasal cycle after use of vasoconstricting nasal drops and maintaining a spraying angle of 45 degrees upwards
Number of subjects: 18
Study 7590022 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1.0 mg)
Number of subjects: 31
Study 7590022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 7590022 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of flumazenil (0.25 mg/h)
Number of subjects: 31
Study 7590022 — intervention group
Group type: EXPERIMENTAL
Intervention: Open study with flumazenil (1.0 mg)
Number of subjects: 31
Study 1962892 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol 40 mg/day orally
Number of subjects: 20
Study 1962892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6110819 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD 1
Number of subjects: 483
Study 6110819 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD 2
Number of subjects: 483
Study 6110819 — intervention group
Group type: COMPARATOR
Intervention: Nova-T device
Number of subjects: 483
Study 6110819 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUDs
Number of subjects: 483
Study 28647339 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (1500mg/day for 7 days)
Number of subjects: 55